🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

'Crafted at Home, NexCar19 takes India to Next level in Cancer Care' Kudos to Dr Purwar & team for their efforts,perseverance leading to #MadeInIndia #NexCar19 CAR-T cell Therapy in India :Details by Soujanya Paddikal #Cancer #CancerResearch #cure #Medicine #Science #UPSC

I am extremely honored to be in 2024 Time100 Health list for my contribution in lowering cancer costs. lnkd.in/eszZ-BfW Thanks to Rahul Purwar Gaurav Narula MD Hasmukh Jain Atharva Karulkar and all the team members for their incredible support and help to bring CAR T in India.

Congratulations Alka Dwivedi

Congratulations to Dr. Alka Dwivedi @NCIResearchCtr on being named one of TIME Health’s 100 most influential people in health in 2024! Her global efforts will help bring affordable CAR-T cell therapy to cancer patients in India. This is remarkable work! time.com/6968932/alka-d… 👏

Thank a million Dr. Kimryn Rathmell Dr. Kimryn Rathmell. I would like to thank NCI scientists Nirali Shah 河北外围：石家庄邯郸唐山保定秦皇岛邢台张家口承德沧州廊坊衡水南宫沙河冀州深州 and Dr. Terry Fry for their tremendous support and contribution in bringing affordable and accessible CAR in India.

Explaining CAR-T cell therapy to guests in Japan at Indian Embassy in Japan. Hoping to initiate some good collaboration between two great nations.

Annual Research Round Up with the Lipsett Auditorium as full as prepandemic as we heard excellent talks after hallways alive with posters full of exciting science & medicine! Go @NCI_CCR_PedOnc @NCIResearchCtr National Cancer Institute

Emily's story inspired millions & our own #CARTCellRx Tata Memorial Hospital Rahul Purwar IIT Bombay So when Ishwari Rx'd on 1st Phase 1 trial 🇮🇳 t'was only "CARma" they meet! Magic 🪄 courtesy Emily Whitehead Foundation ImPaCCT Foundation thanks to Tom Whitehead Shalini Jatia CAR-T & Cell Therapy Centre (CTCTC) ACTREC_TMC Albeena Nisar 📹🔗X👇

With over 150 infusions of #NexCAR19 in India so far, we are continuously engaging with the haemato-oncology community in ensuring that #CARTcelltherapy is accessible, affordable, and a viable treatment option in the management of refractory/relapsing B-ALL and B-cell Lymphomas.

Indeed!!! This was the need of Indian research institutions. Accessibility of journals will help tremendously in innovative research and bringing India forward in research and development field.

Rahul Purwar , Director de INMUNOACT.Generoso y extraordinario científico que desarrolló la Inmunoterapia contra Leucemia en la India y ahora lo hará en México con apoyo del Dr. Kershenobich, el IPN y Nutrición.Nuestra gratitud siempre !!

An inspiring and admirable experience. It was a pleasure to receive you! ImmunoACT Rahul Purwar Hasmukh Jain

Huge thanks Honourable Secretary Marcelo Ebrard for the wonderful meeting and discussion on potential collaboration.

Huge thanks to Dr Bahl and ICMR and GST Council for helping the patients with exemption of GST in gene therapy. This timely help from PMO India and Ministry of Finance will help #makeinindia Gene therapy (CAR-T cells) accessable to all patients.

Thanks for the shoutout Satya Prakash Yadav Really happy to’ve presented Indian Cell & Gene Rx journey ASTCT #Tandem25 Great discussion on the stuff that matters to all! Innovation, Cost/Price, Market reach, Access & Equity Tata Memorial Hospital ImPaCCT Foundation CAR-T & Cell Therapy Centre (CTCTC) ACTREC_TMC Rahul Purwar Albeena Nisar

Access of CAR-T is essential for patients in global south- majority of Asia (probably except China and Japan), Latin America and Africa still don't have access. We need to find new ways to make it more affordable to ensure access.

Our Founder, Prof. Rahul Purwar, received the Prof. Ranjit Roy Chaudhury Oration at the 18th ISCR Conference for advancing clinical research in India. He emphasized collaboration and shared insights from conducting Phase I/II CAR-T trials in an uncharted landscape.

Publication alert for India's first CAR-T cell therapy, NexCAR19 for B- cell leukemia and B-cell lymphoma. Much awaited publication.

Much awaited publication for this remarkable collaborative effort of Tata Memorial Hospital, IIT Bombay, ImmunoACT in bringing affordable and effective CAR-T cell therapy to our patients.

Happy to share an excellent ORR at three dose levels in pediatric patients with HCAR19, India’s first CD19 CAR T. Do read the article rdcu.be/ei7xh